PL2808340T3 - Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację - Google Patents

Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Info

Publication number
PL2808340T3
PL2808340T3 PL14178729T PL14178729T PL2808340T3 PL 2808340 T3 PL2808340 T3 PL 2808340T3 PL 14178729 T PL14178729 T PL 14178729T PL 14178729 T PL14178729 T PL 14178729T PL 2808340 T3 PL2808340 T3 PL 2808340T3
Authority
PL
Poland
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
including alpha
Prior art date
Application number
PL14178729T
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2808340(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of PL2808340T3 publication Critical patent/PL2808340T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL14178729T 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację PL2808340T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25

Publications (1)

Publication Number Publication Date
PL2808340T3 true PL2808340T3 (pl) 2017-02-28

Family

ID=39717519

Family Applications (6)

Application Number Title Priority Date Filing Date
PL16194925T PL3144318T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację
PL14178729T PL2808340T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL16179121.5T PL3098234T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL21212873.0T PL4015527T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL16158141T PL3045471T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL09733497T PL2268666T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16194925T PL3144318T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh obejmujący alfa 2,3- oraz alfa 2,6-sialilację

Family Applications After (4)

Application Number Title Priority Date Filing Date
PL16179121.5T PL3098234T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL21212873.0T PL4015527T3 (pl) 2008-04-16 2009-04-16 Rekombinowany fsh zawierający alfa 2,3- i alfa 2,6-sialilację
PL16158141T PL3045471T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację
PL09733497T PL2268666T3 (pl) 2008-04-16 2009-04-16 Rekombinowany FSH zawierający alfa 2,3- i alfa 2,6-sialilację

Country Status (29)

Country Link
US (6) US8951967B2 (pl)
EP (7) EP2268666B1 (pl)
JP (7) JP2011519359A (pl)
KR (5) KR20170110741A (pl)
CN (3) CN102066414A (pl)
AR (1) AR071479A1 (pl)
AU (5) AU2009237479B2 (pl)
BR (1) BRPI0910461B8 (pl)
CA (1) CA2725257A1 (pl)
CY (1) CY1115413T1 (pl)
DK (6) DK2268666T3 (pl)
ES (5) ES3023526T3 (pl)
FI (4) FI4015527T3 (pl)
FR (3) FR17C1020I2 (pl)
HR (5) HRP20250313T1 (pl)
HU (9) HUE071059T2 (pl)
IL (2) IL208538A (pl)
LT (8) LT3098234T (pl)
MX (3) MX2010011343A (pl)
NO (4) NO2017025I1 (pl)
NZ (1) NZ588381A (pl)
PL (6) PL3144318T3 (pl)
PT (6) PT3144318T (pl)
RU (3) RU2537268C2 (pl)
SA (1) SA109300228B1 (pl)
SI (6) SI3098234T1 (pl)
TW (1) TWI488640B (pl)
WO (1) WO2009127826A1 (pl)
ZA (1) ZA201007373B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
JP5918697B2 (ja) 2010-10-15 2016-05-18 Ｊｃｒファーマ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
CA2831486A1 (en) * 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2013161958A1 (ja) * 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
ES2784625T3 (es) 2015-04-17 2020-09-29 Ferring Bv FSH para el tratamiento de la infertilidad
JP6845813B2 (ja) 2015-06-26 2021-03-24 フェリング ベスローテン フェンノートシャップ 精製および／またはウイルス不活性化の方法
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
EP4427806A3 (en) 2017-09-01 2024-10-09 Ferring B.V. Composition for controlled ovarian stimulation
SI3787667T1 (sl) 2018-04-30 2025-06-30 Ferring B.V. Sestavek za nadzorovano stimulacijo jajčnikov
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
US20250241993A1 (en) 2022-04-01 2025-07-31 Ferring B.V. Mixed protocol for treatment of infertility
EP4531895A1 (en) 2022-05-26 2025-04-09 Ferring B.V. Compositions and methods for treatment of infertility in males
MA71382A (fr) 2022-07-08 2025-04-30 Ferring B.V. Compositions et procédés d'insémination intra-utérine (iiu)
WO2025017533A1 (en) 2023-07-20 2025-01-23 Ferring B.V. Extended release drug-loaded microparticles

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
PT833934E (pt) 1995-06-15 2005-02-28 Crucell Holland Bv Sistemas de empacotamento para adenovivrus recombinente humano destinados a terapia genetica
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
ATE263841T1 (de) 1997-01-16 2004-04-15 Neose Technologies Inc Praktische in vitro sialylierung von rekombinanten glykpproteinen
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
SI1176976T2 (sl) 1999-05-07 2015-12-31 Merck Serono Sa Uporaba LH, dajanega v srednji ali pozni folikularni fazi, za zdravljenje anovulatornih žensk
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
MEP38608A (en) * 2001-10-22 2011-02-10 Merck Serono Sa Gonadotrophins for folliculogenesis
CA2756610C (en) 2001-10-29 2015-08-25 Crucell Holland B.V. Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2005056760A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
EP1711834B1 (en) 2004-02-04 2010-08-04 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
EP1725673A1 (en) 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
CA2831486A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
ES2468318T3 (es) 2014-06-16
LT2808340T (lt) 2016-11-10
US8951967B2 (en) 2015-02-10
NO2025006I1 (no) 2025-01-16
CY1115413T1 (el) 2017-01-04
JP6762916B2 (ja) 2020-09-30
IL208538A (en) 2014-03-31
IL230571A (en) 2015-11-30
ZA201007373B (en) 2011-06-29
RU2537268C2 (ru) 2014-12-27
NO2025032I1 (no) 2025-07-14
US20150065695A1 (en) 2015-03-05
RU2010141908A (ru) 2012-05-27
JP2020040956A (ja) 2020-03-19
AU2017225020B2 (en) 2019-11-14
AU2017204259B2 (en) 2017-08-17
SI3045471T1 (sl) 2017-07-31
US20160347811A1 (en) 2016-12-01
HUS1700036I1 (hu) 2017-10-30
JP2011519359A (ja) 2011-07-07
HRP20161520T1 (hr) 2016-12-30
DK2268666T3 (da) 2014-05-12
HUE068565T2 (hu) 2025-01-28
EP2268666B1 (en) 2014-03-12
RU2682270C2 (ru) 2019-03-18
US11952407B2 (en) 2024-04-09
AU2014203277B2 (en) 2017-04-06
FIC20250003I1 (fi) 2025-01-15
KR102108377B1 (ko) 2020-05-08
EP2808340A1 (en) 2014-12-03
DK4015527T3 (da) 2025-04-14
IL208538A0 (en) 2010-12-30
JP7316905B2 (ja) 2023-07-28
PT3045471T (pt) 2017-06-14
FR25C1003I1 (fr) 2025-02-28
HUE030652T4 (en) 2017-09-28
ES3023526T3 (en) 2025-06-02
DK2808340T3 (en) 2016-12-05
JP2018021037A (ja) 2018-02-08
FR17C1020I1 (pl) 2020-04-10
HUE033830T2 (en) 2018-01-29
AU2017204258A1 (en) 2017-07-20
DK3045471T3 (en) 2017-06-26
LTPA2025525I1 (pl) 2025-07-25
SI4015527T1 (sl) 2025-05-30
JP2015120696A (ja) 2015-07-02
US9546204B2 (en) 2017-01-17
US20240327487A1 (en) 2024-10-03
EP4015527A1 (en) 2022-06-22
MX348622B (es) 2017-06-22
EP2268666A1 (en) 2011-01-05
LTPA2017029I1 (lt) 2017-10-10
BRPI0910461A2 (pt) 2018-03-27
PL3098234T3 (pl) 2025-01-07
AR071479A1 (es) 2010-06-23
AU2017225020A1 (en) 2017-09-28
HK1146284A1 (en) 2011-05-20
EP3098234A1 (en) 2016-11-30
WO2009127826A1 (en) 2009-10-22
PT2268666E (pt) 2014-06-25
JP2024038000A (ja) 2024-03-19
SI2808340T1 (sl) 2016-12-30
FI3098234T3 (fi) 2024-10-31
HRP20170958T1 (hr) 2017-09-22
BRPI0910461B8 (pt) 2021-05-25
LT3045471T (lt) 2017-07-10
PT4015527T (pt) 2025-04-10
HK1199039A1 (en) 2015-06-19
FIC20250025I1 (fi) 2025-07-11
EP2722339A1 (en) 2014-04-23
CN102066414A (zh) 2011-05-18
EP3144318A1 (en) 2017-03-22
EP3098234B1 (en) 2024-07-31
TW200948378A (en) 2009-12-01
SA109300228B1 (ar) 2014-04-08
US20110105398A1 (en) 2011-05-05
NO2017025I1 (no) 2017-06-06
KR20190092608A (ko) 2019-08-07
CN105906702A (zh) 2016-08-31
RU2745557C1 (ru) 2021-03-29
HUE071059T2 (hu) 2025-07-28
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
FR17C1020I2 (fr) 2020-04-10
SI3144318T1 (sl) 2020-12-31
EP2808340B1 (en) 2016-08-17
LT3098234T (lt) 2024-09-10
PT2808340T (pt) 2016-11-21
SI3098234T1 (sl) 2024-10-30
RU2014141994A3 (pl) 2018-05-28
DK3098234T3 (da) 2024-10-21
FR25C1025I1 (fr) 2025-09-19
AU2014203277A1 (en) 2014-07-24
KR20180095140A (ko) 2018-08-24
CN105906703A (zh) 2016-08-31
AU2017204259A1 (en) 2017-07-20
EP4015527B1 (en) 2025-01-22
US20180079794A1 (en) 2018-03-22
RU2014141994A (ru) 2016-05-10
AU2014203277C1 (en) 2017-07-27
EP3045471B1 (en) 2017-03-29
PL3045471T3 (pl) 2017-10-31
PL2268666T3 (pl) 2014-08-29
CA2725257A1 (en) 2009-10-22
JP2017060476A (ja) 2017-03-30
RU2745557C3 (ru) 2021-12-10
US9771407B2 (en) 2017-09-26
TWI488640B (zh) 2015-06-21
KR20110005863A (ko) 2011-01-19
KR20160056960A (ko) 2016-05-20
US20210332099A1 (en) 2021-10-28
PL3144318T3 (pl) 2021-02-08
DK3144318T3 (da) 2020-12-07
KR101622944B1 (ko) 2016-05-23
BRPI0910461B1 (pt) 2021-02-23
AU2009237479B2 (en) 2014-05-15
HUS1700024I1 (hu) 2017-06-28
HRP20250313T1 (hr) 2025-05-09
AU2009237479A1 (en) 2009-10-22
LT4015527T (lt) 2025-04-10
ES2989729T3 (es) 2024-11-27
EP3045471A1 (en) 2016-07-20
BRPI0910461A8 (pt) 2018-10-16
PT3144318T (pt) 2020-11-04
PT3098234T (pt) 2024-10-21
KR20170110741A (ko) 2017-10-11
EP3144318B1 (en) 2020-09-23
US10995128B2 (en) 2021-05-04
HUE030652T2 (en) 2017-05-29
LTPA2025505I1 (pl) 2025-02-10
NO2017050I1 (no) 2017-09-28
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
NZ588381A (en) 2012-05-25
JP2022031652A (ja) 2022-02-22
HRP20241187T1 (hr) 2024-12-06
SI2268666T1 (sl) 2014-07-31
MX355457B (es) 2018-04-19
HUS2500029I1 (hu) 2025-07-28
HUS2500008I1 (hu) 2025-02-28
JP6486310B2 (ja) 2019-03-20
HUS1700025I1 (hu) 2017-06-28
LTPA2017018I1 (lt) 2017-06-26
ES2629392T3 (es) 2017-08-09
AU2017204258B2 (en) 2017-08-17
FI4015527T3 (fi) 2025-04-29

Similar Documents

Publication Publication Date Title
HUS2500029I1 (hu) Alfa 2,3- és alfa 2,6-szalizációt tartalmazó rekombináns FSH
SI3581631T1 (sl) Sestavki, ki obsegajo 2,3,3,3-tetrafluoropropen
IL211762A (en) Pegillacie opioids, preparations containing them and their uses
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
ZA201005346B (en) 3,8-diaminotetrahydroquinoline derivative
AP2010005388A0 (en) Pupicidal and larvicidal composition.
IL207174A0 (en) Peptides, compositions, and uses thereof
LT3144318T (lt) Rekombinantinis fsh, įskaitant alfa-2,3- ir alfa-2,6-sialilinimą
GB0808401D0 (en) Fsh
GB0813815D0 (en) Corcost Pre 1001,10
GB0809709D0 (en) Dunhill car,2093
GB0705503D0 (en) The buffer
GB0808811D0 (en) Algabe 2.1